Comparison of clinical and laboratory findings between subgroups with primary Sjögren’s syndrome patients
| Characteristics | Children (n=13) | Men (n=12) | Female (n=30) | p Value |
| Age at onset (y) (mean(SD)) | 9.4 (2.8) | 45.3 (5.5) | 46.4 (6.1) | |
| Disease duration (y) (mean(SD)) | 6.5 (3.2) | 11.2 (5.0) | 10.5 (5.4) | |
| First manifestations | ||||
| Sicca syndrome | 3 (23%) | 9 (75%)* | 23 (77%)† | p < 0.05*, p < 0.005† |
| RPGE | 10 (77%) | 2 (17%)* | 4 (13%)† | p < 0.01*, p < 0.0001† |
| EGM | — | 1 (8%) | 3 (10%) | NS |
| Extraglandular manifestations during disease | ||||
| Constitutional symptoms | 3 (23%) | 4 (33%) | 7 (23%) | NS |
| Musculoskeletal | 3 (23%) | 1 (8%) | 14 (47%) | p < 0.05 |
| Raynaud’s phenomenon | 4 (31%) | 1 (8%) | 13 (43%) | p < 0.05 |
| Lymphadenopathy | 3 (23%) | 4 (33%) | 5 (17%) | NS |
| Hepatomegaly | 1 (8%) | 2 (17%) | 4 (13%) | NS |
| Skin involvement | — | — | 1 (3%) | NS |
| Pulmonary involvement | — | — | 1 (3%) | NS |
| Autoantibodies | ||||
| RF | 6 (46%) | 8 (67%) | 16 (53%) | NS |
| ANA | 9 (69%) | 4 (33%) | 23 (77%) | p < 0.025 |
| Ro (SSA) | 7 (54%) | 2 (17%) | 19 (63%) | p < 0.025 |
| La (SSB) | 4 (31%) | 1 (8%) | 11 (37%) | NS |
RPGE = recurrent parotid gland enlargement; EGM = extraglandular manifestations. * = statistically significant between children and men. † = statistically significant between children and women.